Navigation Links
HYALGAN® (sodium hyaluronate) Commercial Rights Transfer Back to Fidia Farmaceutici S.p.A.
Date:9/15/2011

PARSIPPANY, N.J., Sept. 15, 2011 /PRNewswire/ -- Fidia Farmaceutici S.p.A. (Fidia) announced today that commercial rights for HYALGAN ® (sodium hyaluronate), an injectable treatment for knee pain caused by osteoarthritis when simple painkillers or exercise and physical therapy are not enough, will be transferred from Sanofi US LLC back to Fidia on September 24, 2011.  Fidia Farmaceutici S.p.A. is the owner and manufacturer of HYALGAN. After September 24th, Fidia will promote, distribute and sell HYALGAN in the United States through its wholly owned subsidiary, Fidia Pharma USA Inc, headquartered in Parsippany, N.J.

The company stated that the transfer of US commercial responsibility for HYALGAN will not result in any change to the product. Current volume purchase agreements will continue to be honored and the product's current J-code will remain unchanged.  Critical services such as the HYALGAN® patient assistance program will also remain unchanged and can be accessed at 1-866-7-HYALGAN. Until September 24th, medical professionals can direct their questions about HYALGAN to their Sanofi US LLC sales representative.

HYALGAN was approved for marketing by the U.S. Food and Drug Administration in 1997.  More than 38 million doses of HYALGAN® have been administered worldwide since its introduction.(1)

About Fidia Farmaceutici S.p.A

Headquartered in Abano Terme, Northeast Italy, Fidia Farmaceutici S.p.A., has over 50 years of successful R&D and industry experience with biologically active molecules.  As a model for international success, Fidia has focused its core business activities on hyaluronic acid, developing and providing a wide range of products for various specialties. Fidia holds more than 960 patents on hyaluronic acid and its applications and its products are currently in over 70 countries worldwide.  Fidia's most important proprietary platform technology at
'/>"/>

SOURCE Fidia Farmaceutici S.p.A.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
2. Jazz Pharmaceuticals Announces FDA Acceptance of its New Drug Application for JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia
3. Jazz Pharmaceuticals Provides Update on FDA Advisory Committee Meeting For JZP-6 (Sodium Oxybate) in Fibromyalgia
4. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
5. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
8. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
9. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
10. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
11. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  The Healthcare Analytics Summit 2014 (HAS ... Salt Lake City , Sept. 24-25 has added ... organizations in the U.S. and beyond.  HAS ,14, powered ... devoted to providing immersive learning experiences on the ... accountable care initiatives and population health managemen t ...
(Date:7/29/2014)... MOUNTAIN VIEW, Calif. , July 29, 2014 ... antivirals has amplified with rising incidence rates and ... absence of a preventative vaccine. Change is underway ... and interferon regimens towards highly effective, easily-tolerated, interferon-free ... http://photos.prnewswire.com/prnh/20140728/130662 Gilead,s mega blockbuster ...
(Date:7/29/2014)... LONDON , July 29, 2014 ... 2014 Global Frost & Sullivan Best Practices Award ... solution is a cloud-based platform that connects digital ... - such as providers, pharmaceutical companies, prevention and ... electronics. Each year, Frost & ...
Breaking Medicine Technology:Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 2Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 4
... ZURICH , July 19, 2010 Today, Novo Nordisk ... designed to investigate the effects of modern insulins in,the management of type 2 diabetes.[1] ... Spanning 28 countries across ... largest observational study,in insulin therapy. , , ...
... July 16 Human erythropoietin (EPO) is a ... and spinal cord injury, and Parkinson,s disease. However, EPO drug ... cross the blood-brain barrier (BBB). In acute stroke or brain ... the insult when neuroprotection is still possible. Therefore, large molecule ...
Cached Medicine Technology:World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 2World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 3ArmaGen® Re-engineers Erythropoietin for Brain Penetration 2
(Date:7/29/2014)... rates rise in association with extremely hot weather. The ... 2003, for example, resulted in about 22,000 extra deaths. ... at the Institute of Epidemiology II at the Helmholtz ... the number of deaths caused by cardiovascular disease in ... temperatures in the study. , "Our findings confirm the ...
(Date:7/29/2014)... handle stressful situations better than others, and it,s ... show differences in how they respond. , Researchers ... brains of genetically identical mice that predicts how ... , The findings, published July 29 in ... prevent potential consequences of chronic stress -- such ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Foot Levelers ... lecturer at the Florida Chiropractic Association (FCA) National Convention ... Effects on the Kinetic Chain Changes on Thursday, August ... talk is focusing on the positive impact functional foot ... such as low back pain, plantar fasciitis, and hammertoes. ...
(Date:7/29/2014)... Dallas, Texas (PRWEB) July 29, 2014 ... the Global Biosimilars Market report is an essential ... biosimilars industry. Using detailed company data, financial analysis, ... in-depth analysis of the current and future growth ... the various regulatory frameworks under which biosimilars are ...
(Date:7/29/2014)... Catalent Pharma Solutions, the global leader ... for pharmaceutical, biologic, and consumer health products, today ... US Platform Leader of Pharmaceutical Softgels, will present ... Formulations using Soft Capsule Delivery Systems” at the ... of Drug Delivery Systems (30-31 July 2014, Tokyo, ...
Breaking Medicine News(10 mins):Health News:Mortality rates increase due to extreme heat and cold 2Health News:A new brain-based marker of stress susceptibility 2Health News:Foot Levelers CEO Kent Greenawalt Speaking at FCA Convention 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 3Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 4Health News:Catalent Expert to Present on Enhancing Bioavailability of Poorly Absorbed Drugs at Japan Society of Drug Delivery Systems 2
... of Oaks Development,Group announced today the company closed on ... 3603 Paesanos Parkway in north central,San Antonio. The ... 1604 and,Northwest Military Highway, will feature the company,s unique ... tenants, equity,investors and the developer. , ...
... and John Centrello decided to bank their baby,s cord blood with M.A.Z.E. ... hoping never to use it, but wanted to have it just in ... ... While pregnant, Danielle and John Centrello decided to bank their baby,s ...
... December 8, 2008Medical specialists at the nation,s largest professional ... have about data presented by the FDA in support ... and the potential effect of the federal agency,s analyses ... are to be conducted in the future. , It ...
... Unilens Vision Inc.,(OTC Bulletin Board: UVICF; TSX Venture ... specialty contact lenses,today announced the acquisition of the ... Inc. located in Michigan. , ... agreement, Unilens acquired certain assets of Aero,Contact Lens, ...
... chronic hepatitis C and advanced liver disease with long-term ... and liver inflammation, but the treatment did not slow ... study finds. , These findings come from the clinical ... and are reported in the Dec. 4 issue of ...
... Cancer Report Released by IARC; U.S. Groups List Six Critical Steps ... , ATLANTA, Dec. 9 Despite ... men and women in the United States continue to decline, cancer ... the year 2010, and low- and middle-income countries will feel the ...
Cached Medicine News:Health News:Oaks Development Group Closes on Third San Antonio Project 2Health News:Oaks Development Group Closes on Third San Antonio Project 3Health News:Local Child Treated In Clinical Trial To Ease Symptoms of Cerebral Palsy 2Health News:Local Child Treated In Clinical Trial To Ease Symptoms of Cerebral Palsy 3Health News:Local Child Treated In Clinical Trial To Ease Symptoms of Cerebral Palsy 4Health News:Unilens Vision Acquires Aero Contact Lens, Inc. 2Health News:Hepatitis C treatment reduces the virus but liver damage continues 2Health News:Hepatitis C treatment reduces the virus but liver damage continues 3Health News:Leading U.S. Cancer Organizations Unite Against the Growing Global Cancer Burden 2Health News:Leading U.S. Cancer Organizations Unite Against the Growing Global Cancer Burden 3Health News:Leading U.S. Cancer Organizations Unite Against the Growing Global Cancer Burden 4Health News:Leading U.S. Cancer Organizations Unite Against the Growing Global Cancer Burden 5Health News:Leading U.S. Cancer Organizations Unite Against the Growing Global Cancer Burden 6
... Used to dilate the lower ... to assess possible submucosal tunneling. ... topical anesthetic in the ureter. ... by, or dislodgment of a ...
Used for drainage and retrograde pyelogram. The spiral tip aids in negotiation of a tortuous or partially obstructed ureter. Supplied sterile in peel-open packages. Intended for one-time use....
... Used for the injection of contrast ... The dual lumen design eliminates the need ... designed to promote atraumatic passage into and ... layer of hydrophilic polymer that when activated, ...
Used for drainage and retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: